ArticlePloS one2013
Co-therapy using lytic bacteriophage and linezolid: effective treatment in eliminating methicillin resistant Staphylococcus aureus (MRSA) from diabetic foot infections.
Article in PloS one, 2013. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 108 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
108 citing papers in PubMed, 200 citations in OpenAlex.
- Harnessing phage-ciprofloxacin synergy to overcome multidrug-resistant infections and biofilm persistence.Archives of microbiology · 2026Article
- Bacteriophage therapy and antimicrobial resistance: a scoping review using the "One Health" framework.Infection · 2026Review
- Phage therapy for treatment of bacterial vaginosis.Archives of microbiology · 2026Review
- Bacteriophage research in India and its implications for human health: A scoping review.The Indian journal of medical research · 2026Article
- Spot-on phage therapy: stable formulations, smarter dosing for topical phage application.Frontiers in cellular and infection microbiology · 2026Review
- Management of Diabetic Foot Infections Using Phage Therapy.Infection and drug resistance · 2026Review
- Integrating clinical data into evidence-based practice: institutional guideline development for diabetic foot infections.Frontiers in endocrinology · 2026Article
- A Novel Therapeutic Approach: Phage andScientifica · 2026Article
- Isolation of Lytic Bacteriophages ofVeterinary sciences · 2025Article
- Innovative Non-antibiotic Strategies for Combating Methicillin-Resistant Staphylococcus aureus in Diabetic Foot Infections.Current microbiology · 2025Review
- Phage therapy: a promising approach forJournal of virology · 2025Review
- Understanding current challenges of antibiotic resistance to find new solutions for 2050: scientific, medical and political issues.Archives of microbiology · 2025Review
- Piezoelectric biosensor with dissipation monitoring enables the analysis of bacterial lytic agent activity.Scientific reports · 2025Article
- Genomic Insights into and Lytic Potential of Native Bacteriophages M8-2 and M8-3 Against Clinically Relevant Multidrug-ResistantAntibiotics (Basel, Switzerland) · 2025Article
- Phage-Derived Endolysins Against Resistant Staphylococcus spp.: A Review of Features, Antibacterial Activities, and Recent Applications.Infectious diseases and therapy · 2025Review
- Understanding and treating diabetic foot ulcers: Insights into the role of cutaneous microbiota and innovative therapies.Skin health and disease · 2024Review
- Review
- Article
- Efficacy and clinical potential of phage therapy in treating methicillin-resistant Staphylococcus aureus (MRSA) infections: A review.European journal of microbiology & immunology · 2024Review
- Article
48 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundStaphylococcus aureus remains the predominant pathogen in diabetic foot infections and prevalence of methicillin resistant S.aureus (MRSA) strains further complicates the situation. The incidence of MRSA in infected foot ulcers is 15-30% and there is an alarming trend for its increase in many countries. Diabetes acts as an immunosuppressive state decreasing the overall immune functioning of body and to worsen the situation, wounds inflicted with drug resistant strains represent a morbid combination in diabetic patients. Foot infections caused by MRSA are associated with an increased risk of amputations, increased hospital stay, increased expenses and higher infection-related mortality. Hence, newer, safer and effective treatment strategies are required for treating MRSA mediated diabetic foot infections. The present study focuses on the use of lytic bacteriophage in combination with linezolid as an effective treatment strategy against foot infection in diabetic population. METHODOLOGY: Acute hindpaw infection with S.aureus ATCC 43300 was established in alloxan induced diabetic BALB/c mice. Therapeutic efficacy of a well characterized broad host range lytic bacteriophage, MR-10 was evaluated alone as well as in combination with linezolid in resolving the course of hindpaw foot infection in diabetic mice. The process of wound healing was also investigated. RESULTS AND
conclusionsA single administration of phage exhibited efficacy similar to linezolid in resolving the course of hindpaw infection in diabetic animals. However, combination therapy using both the agents was much more effective in arresting the entire infection process (bacterial load, lesion score, foot myeloperoxidase activity and histopathological analysis). The entire process of tissue healing was also hastened. Use of combined agents has been known to decrease the frequency of emergence of resistant mutants, hence this approach can serve as an effective strategy in treating MRSA mediated foot infections in diabetic individuals who do not respond to conventional antibiotic therapy.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.